Alzheon Moves Forward With Tramiprosate Development in Select Alzheimer’s Patients
Data from Phase 3 trials of tramiprosate (ALZ-801) suggest that the therapy might be modifying the disease course in patients with mild Alzheimer’s disease and two copies of the APOE4 gene, the drug’s developer, Alzheon, recently announced. With data in hand, the Framingham, Massachusetts, company plans to further clinical…